课题基金 / 基金详情

CLINICAL TRIAL: A DOUBLE BLIND, PLACEBO CONTROLLED, PHASE II, RANDOMIZED STUDY O

CLINICAL TRIAL: A DOUBLE BLIND, PLACEBO CONTROLLED, PHASE II, RANDOMIZED STUDY O
临床试验:双盲、安慰剂对照、第二阶段、随机研究
批准号:
7719295
负责人:
Cynthia Aranow
金额:
$1.01万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-22 至 2009-03-31

项目摘要

项目成果

Cynthia Aranow的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at the effects of a drug called lovastatin in the treatment of patients with mildly active rheumatoid arthritis (RA). Lovastatin is one of the "statin" drugs approved by the FDA for the treatment of high cholesterol, but it is currently not approved for treating RA. There is evidence from laboratory studies that lovastatin may be beneficial in the treatment of mildly active RA. One purpose of this study is to determine if lovastatin is effective in reducing the inflammation that is seen in patients with mildly active RA. Another purpose is to see if it safe for treatment of mildly active RA. This study will look at the effects of lovastatin by comparing subjects with RA who are receiving the study drug, lovastatin, to those who do not.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Nontoxic Therapeutic Interventions for Autoimmune Inflammatory Disease
Novel Nontoxic Therapeutic Interventions for Autoimmune Inflammatory Disease
Novel Nontoxic Therapeutic Interventions for Autoimmune Inflammatory Disease
Novel Nontoxic Therapeutic Interventions for Autoimmune Inflammatory Disease
海外基金